Compare NTNX & SNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NTNX | SNN |
|---|---|---|
| Founded | 2009 | 1856 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Industrial Specialties |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.1B | 14.3B |
| IPO Year | 2015 | N/A |
| Metric | NTNX | SNN |
|---|---|---|
| Price | $39.29 | $32.94 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 16 | 2 |
| Target Price | ★ $64.33 | $36.25 |
| AVG Volume (30 Days) | ★ 4.2M | 841.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | ★ 2.28% |
| EPS Growth | ★ 227.45 | N/A |
| EPS | ★ 0.57 | N/A |
| Revenue | ★ $2,537,927,000.00 | N/A |
| Revenue This Year | $13.91 | $7.19 |
| Revenue Next Year | $13.28 | $5.36 |
| P/E Ratio | $68.49 | ★ $64.97 |
| Revenue Growth | ★ 18.11 | N/A |
| 52 Week Low | $35.39 | $23.91 |
| 52 Week High | $83.36 | $38.79 |
| Indicator | NTNX | SNN |
|---|---|---|
| Relative Strength Index (RSI) | 44.11 | 37.60 |
| Support Level | $35.84 | $32.08 |
| Resistance Level | $42.63 | $33.89 |
| Average True Range (ATR) | 1.76 | 0.71 |
| MACD | 0.19 | -0.44 |
| Stochastic Oscillator | 48.20 | 11.80 |
Nutanix Inc is engaged in cloud software, offering organizations a single platform for running applications and managing data anywhere. Its Nutanix Cloud Platform is designed to enable organizations to build a hybrid multicloud infrastructure, providing a consistent cloud operating model with a single platform for running applications and managing data in core data centers, at the edge, and in public clouds, all while supporting a variety of hypervisors and container platforms. The company operates a single operating and reportable segment based on a subscription business model. It conducts business in the United States, Europe, the Middle East and Africa, Asia Pacific, and other Americas, with key revenue generated from the United States.
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 41% of the UK-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.